Evidence map›Paper›PMID 25493592›Full record

ArticleAIDS (London, England)2014

Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

Gert U van Zyl, Lisa M Frenkel, Michael H Chung, Wolfgang Preiser, John W Mellors, Jean B Nachega

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gert U van ZylaDivision of Medical Virology, Department of Pathology, Stellenbosch University and National Health Laboratory Service Tygerberg, Cape Town, South Africa bDepartments of Pediatrics, Laboratory Medicine and Global Health, University of Washington, and Seattle Children's Research Institute cDepartments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington, USA dDepartment of Medicine and Center for Infectious Diseases, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa eDepartments of International Health and Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland fDivision of Infectious Diseases, Department of Medicine gDepartment of Epidemiology, Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Lisa M Frenkel
Michael H Chung
Wolfgang Preiser
John W Mellors
Jean B Nachega

Funding

Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaU01AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI COTTON, MARK FREDRIC · 2007 to 2011
$8.4M
NIAID NIH HHS 2UM1AI069521-08NIAID NIH HHS UM1 AI069521PEPFAR T84HA21652-01-00Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, ViralAfrica South of the SaharaAnti-Retroviral AgentsHIVHIV InfectionsHumansIncidenceMicrobial Sensitivity TestsAnti-Retroviral Agents

Identifiers

PMID25493592
PMCPMC4784963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.